Yudith Cauna Orocollo

Yudith Cauna Orocollo

Auto-generated profile, based on publicly available information

Yudith Cauna Orocollo

Instituto de Investigaciones en ciencias biomédicas, Universidad Ricardo Palma

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2023 in Revista de la Facultad de Medicina Humana
Verified
Journal Article
Open access
PDF file
UBUniversidad Ricardo Palma. Lima Instituto de Investigaciones En Ciencias Biomédicas
Universidad Ricardo Palma. Lima Instituto de Investigaciones En Ciencias Biomédicas
YOYudith Cauna Orocollo
Yudith Cauna Orocollo
ACAriana Alessandra Cordova
Ariana Alessandra Cordova
JTJhanina Campos Tineo
Jhanina Campos Tineo
The study of different variables, such as pathogenesis, inflammatory profile, identification of therapeutic targets, efficacy of treatments in murine models has proven to be one of the most practical for the preclinical study of triple negative breast cancer (TNBC), the most aggressive subtype of cancer, with limited application of treatments and low survival rate. However, it must be recognized that there are other minors in which the induction of TNBC is being standardized. This review encompasses the different induction methods that have allowed the development of TNBC and the most relevant therapeutic applications by which murine models with TNBC were developed.

8 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
MFManolo Fernandez
Manolo Fernandez
KCKatherine Calderon
Katherine Calderon
ARAldo Rojas-Neyra
Aldo Rojas-Neyra
VVVikram N. Vakharia
Vikram N. Vakharia
RCRicardo Choque-Guevara
Ricardo Choque-Guevara
MZMirko Zimic
Mirko Zimic
The COVID-19 pandemic has claimed the lives of millions of people worldwide and threatens to become an endemic problem, therefore the need for as many types of vaccines as possible is of high importance. Because of the millions of doses required, it is desirable that vaccines are not only safe and effective, but also easy to administer, store, and inexpensive to produce. Newcastle Disease Virus (NDV) is responsible for a respiratory disease in chickens. It has no pathogenic homologue in humans. NDV is recognized as an oncolytic virus, and its use in humans for oncological treatment is being evaluated. In the present work, we have developed two types of NDV-vectored candidate vaccines, which carry the surface-exposed RBD and S1 antigens of SARS-CoV-2, respectively. These vaccine candidates were produced in specific-pathogen-free embryonating chicken eggs, and purified from allantoic fluid before lyophilization. These vaccines were administered intranasally to three different animal models: mice, rats and hamsters, and evaluated for safety, toxicity, immunogenicity, stability and efficacy. Efficacy was evaluated in a challenge assay against active SARS-CoV-2 virus in the Golden Syrian hamster model. The NDV-vectored vaccine based on the S1 antigen was shown to be safe and highly immunogenic, with the ability to neutralize SARS-CoV-2 in-vitro , even with an extreme dilution of 1/640. Our results reveal that this vaccine candidate protects the lungs of the animals, preventing cellular damage in this tissue. In addition, this vaccine reduces the viral load in the lungs, suggesting that it may significantly reduce the likelihood of transmission. Being lyophilized, this vaccine candidate is very stable and can be stored for several months at 4-8⁰C. In conclusion, our NDV-based vaccine candidate has shown a very favorable performance in the pre-clinical study, serving as evidence for a future evaluation in a Phase-I human clinical trial. This candidate represents a promising tool in the fight against COVID-19.

28 June 2024 in Revista de la Facultad de Medicina Humana
Verified
Journal Article
Open access
PDF file
RLRomina Pinedo Linasca
Romina Pinedo Linasca
YOYudith Cauna Orocollo
Yudith Cauna Orocollo
Intimate partner violence and depression are serious and widespread problems worldwide. According to an analysis of prevalence data in 161 countries from 2000 to 2018 by the WHO, one in three women has suffered physical and/or sexual violence by their partner or sexual violence by someone who was not their partner, or both. In the Western Pacific, the prevalence is 20% and 22% in the European Region and high-income countries (1).